RE:????Here is a good exemple of a contract between Exas:US and Pfizer. The contract end in 2022.
https://www.bizjournals.com/milwaukee/news/2018/08/22/exact-sciences-pfizer-enter-4-year-174m-co.html You will notice that signing a big contract with a large company can be costly.
For now we can assume that SZLS does not have that kind of money (mabe later).
But it could also depend on the conditions of the contract and the return on the money invested.
davewho wrote: Has anyone ever asked or thought whether StageZero would consider selling exclusive rights to ColonSentry for use in the USA? I thinking of EXAS. They should be concerned that ColonSentry will become the test of choice and there goes their rev model. If they purchased the rights then they would cover the full spectrum of patients. Both compliant / ColoGuard and non compliant / ColonSentry and greatly increase their rev model. They certainly would have no trouble raising the cash and SZLS could use that money to develop the next generation Aristotle. Management has indicated Aristotle is not the end of research as there are still many other cancers and diseases to map out. Just wondering. An influx of a 100M or 2 would do wonders for the future of StageZero. The large US Health Groups James is in talks with are more interested in Aristotle than a single test like ColonSentry. Opinions? Just sell the rights not the technology. Or would it be like giving the wolf the keys to the henhouse?